NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

ENOB

ENOB US Stock
$3.99
Open: $3.91 High: $4 Low: $3.7 Close: $3.77
Range: 2021-05-06 - 2021-05-07
Volume: 104,466
Market: Closed
Powered by Finage Stock APIDelayed data
ENOB
  • CEO:
  • Employees:
  • Sector:
  • Industry:
ENOB News
Latest news about the ENOB
  • Is Enochian Biosciences, Inc.'s (NASDAQ:ENOB) Shareholder Ownership Skewed Towards Insiders?

    If you want to know who really controls Enochian Biosciences, Inc. ( NASDAQ:ENOB ), then you'll have to look at the...

    View More →
  • Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy

    LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The important findings were published today, in the peer-reviewed American Journal of Case Reports https://www.amjcaserep.com/abstract/indexMobile/idArt/931030. A complete remission response such as this is uncommon for this highly aggressive and deadly form of brain cancer. In compliance with U.S. Food and Drug Administration guidance, SRI treated the patient with natural killer (NK) and dendritic cells (DC) from a relative who had a partial genetic mismatch. The DCs were loaded with a component of cytomegalovirus that is known to be present in more than 90 percent of glioblastomas. Enochian BioSciences acquired the intellectual property for an approach that is similar to the one used for this successful clinical outcome. The novel, proprietary strategy includes genetic modification of DCs, potentially increasing the immune response and even more effectively attacking tumors. Enochian BioSciences is actively developing this enhanced immune technology, including proof-of-concept in vivo studies of the potential to clear tumors with a focus on pancreatic cancer. In the U.S. alone, more than 60,000 persons are diagnosed with pancreatic cancer, and more than 48,000 die from the disease each year. The treatment strategy also could be applicable to several solid tumors. Dr. Anahid Jewett, a renowned tumor immunologist and cell and gene therapy investigator at UCLA who has developed a humanized mouse model of pancreatic cancer, said: “This exciting clinical finding, as well as many other directions for therapy which Enochian BioSciences is currently undertaking to develop related approaches, gives hope for the possibility of effective treatment for pancreatic cancer and other solid tumors in the future.” About Enochian BioSciences, Inc.Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. The company’s gene-modified cell therapy platform can be applied to multiple indications, including HIV/AIDS, Hepatitis B, and Oncology. About Seraph Research InstituteSeraph Research Institute is a Los Angeles-based non-profit research institution, which runs basic science, translational and clinical research in pursuit of cures and effective treatments for chronic viral infections, cancers, and genetic disorders. Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: Contact: ir@enochianbio.com

    View More →
  • Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

    LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. Executive Vice Chair Dr. Mark Dybul will provide an overview of the company’s progress, including its innovative HIV, Hepatitis B and Oncology platforms. The presentation will be available on-demand for conference attendees beginning at 7 am Eastern on Tuesday, March 9, 2021, and also will be available on the Enochian BioSciences website under the Investors/Media section in Events and Presentations. On March 10, Dr. Dybul and Chief Financial Officer Luisa Puche will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conference. More information on the conference may be found at H.C. Wainwright’s conference website. About Enochian BioSciences Inc.Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV and Oncology. Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: Contact: ir@enochianbio.com

    View More →
  • What You Need To Know About Enochian Biosciences, Inc.'s (NASDAQ:ENOB) Investor Composition

    Every investor in Enochian Biosciences, Inc. (NASDAQ:ENOB) should be aware of the most powerful shareholder groups...

    View More →
  • Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference

    LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B and Oncology platforms at the H.C. Wainwright 22nd Annual Global Investment Conference. Enochian BioSciences’ Executive Vice Chair, Dr. Mark Dybul, will be presenting to a live virtual audience on Tuesday, September 15, 2020 at 2:00 pm Eastern, and will be participating in one-on-one meetings with investors who are registered to attend the conference. A link to the live and archived webcast may be accessed on Enochian’s website under the Investors/Media section in Events and Presentations.More information on the conference may be found at H.C. Wainwright’s conference website.About Enochian BioSciences Inc. Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV and Oncology.Forward-Looking Statements Statements in this presentation that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.  CONTACT: Contact: ir@enochianbio.com

    View More →
  • Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

    Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis BLOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) --  (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the formation of a Scientific Advisory Board (SAB) for one of its promising pipelines. Effective immediately, the Hepatitis B Virus (HBV) Cure SAB will include: * Carol Brosgart, MD, Chairperson of the SAB and member of the Enochian BioSciences Board of Directors and Clinical Professor of Medicine, Biostatistics and Epidemiology, University of California, San Francisco (UCSF) ; * Peter Revill, PhD, Senior Medical Scientist, Victorian Diseases Reference Laboratory, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; and * Fabien Zoulim, MD, PhD, Clinical Professor of Medicine at Lyon University; Medical Director, Hepatology Department, Hospices Civils de Lyon; and Scientific Director, Department of Immunology and Virology, INSERM Unit 1052, France.Chronic HBV liver disease affects approximately 257 million people globally and kills nearly one million people every year. Enochian BioSciences, in partnership with Seraph Research Institute, recently presented data on the scientific progress of its potential HBV cure product at the annual meeting of the American Society of Gene and Cell Therapy (https://www.enochianbio.com/enochian-biosciences-announces-three-scientific-presentations-on-potential-hiv-and-hbv-cures/). The newly formed HBV SAB will provide counsel to help accelerate the development of a potential treatment or cure.Dr. Brosgart joined the Board of Directors of Enochian BioSciences in January, 2020. She is a leader in HBV, HIV and infectious diseases science and industry (https://www.enochianbio.com/enochian-biosciences-a-company-focused-on-gene-modified-cellular-therapy-in-infectious-disease-and-cancer-announces-the-appointment-of-two-board-members/).Dr. Revill and Dr. Zoulim are internationally recognized leaders in HBV cure and treatment research. Dr. Zoulim has published more than 400 peer-reviewed papers, and heads the HBV Cure Task Force of ANRS, the French National Agency for Research on AIDS and Hepatitis, and an autonomous agency within INSERM. INSERM is a government funded agency aiming at improving health through progress in the knowledge of diseases, treatment innovation and public health research. INSERM supports research from bench to bedside and develops its research strategy thanks to partnership with health authorities as well as public and private stakeholders.“The approach Enochian BioSciences has to a potential HBV treatment or cure exploits an innovative pathway that is novel in the field,” said Dr. Zoulim. “The research completed to date already has expanded and validated aspects of our understanding of how HBV functions. I was particularly impressed by the rapid progress Enochian BioSciences has made in such a short period of time. I’m very excited to be advising the company, as we work together to advance from the pre-clinical phase to the potential for effective interventions for people suffering from HBV infection.”Dr. Revill’s work is focused on the molecular virology of HBV, particularly the mechanisms by which HBV causes liver cancer and the contribution of different HBV genotypes and variants to the striking differences in natural history, disease progression and treatment response observed globally. He is an internationally recognized expert in HBV virology, and is passionate about coordinating global efforts to fast track HBV cure. He is the Chair of the Governing Board of the International Coalition to Eliminate HBV (ICE-HBV), initiated in 2015 by Dr. Revill, Dr. Stephen Locarnini and Dr. Fabien Zoulim. He was the co-convenor of the International HBV Meeting held in Melbourne in October 2019, and was also instrumental in organizing the Melbourne Declaration for HBV cure.Dr. Revill said: “I was extremely impressed with Enochian BioSciences’ presentation on its HBV approach and research at the recent HEP DART meeting. When I saw the presentation, my thought was, ‘I really wish I had thought of that.’ The elegant science has the potential to help us reach the Holy Grail – a true cure for HBV. I am thrilled to be advising the company.”“As chair of the newly formed HBV SAB and on behalf of the Enochian BioSciences Board of Directors, I am very pleased to welcome such distinguished scientific leaders to advise us on our path to a new HBV therapy or potential HBV cure,” stated Dr. Brosgart.About Enochian BioSciences Inc. Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV, and Oncology.Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on registration statement on Form S-3 filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.Contact: ir@enochianbio.com

    View More →
  • Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

    LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Initial Targeted Engagement for Regulatory Advice (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT). The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01.

    View More →
  • Company News for May 14, 2020

    Companies In The News Are:

    View More →
  • Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures

    • First presentation of a novel approach to potentially cure HIV  -  An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster.

    View More →